AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11030277 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg/day
Number of subjects: 26
Study 11030277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone proprionate (FP) 200 microg/day
Number of subjects: 26
Study 11030277 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium cromoglycate and beta2-agonist)
Number of subjects: 26
Study 9115051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 52
Study 9115051 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once daily
Number of subjects: 52
Study 8382588 — intervention group
Group type: EXPERIMENTAL
Intervention: 450mg lithium carbonate
Number of subjects: 12
Study 8382588 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mg lithium carbonate
Number of subjects: 12
Study 8382588 — intervention group
Group type: COMPARATOR
Intervention: dopamine infusion
Number of subjects: 12
Study 3730525 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone with modified extent and rate of absorption
Number of subjects: 0
Study 3730525 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis using two-way MANOVA of statistical moments of urinary excretion profiles of canrenone
Number of subjects: 0
Study 31140569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) program, 42 min per day, 5 days per week, over 10 weeks (35 hr total)
Number of subjects: 68
Study 31140569 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC), casual computer games, same duration as CT
Number of subjects: 68
Study 29190126 — intervention group
Group type: EXPERIMENTAL
Intervention: Health news story with intrinsic features of stigma messages
Number of subjects: 200
Study 29190126 — intervention group
Group type: COMPARATOR
Intervention: Health news story without intrinsic features of stigma messages
Number of subjects: 200
Study 30135836 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention for depression (EVIDENT)
Number of subjects: 1013
Study 30135836 — intervention group
Group type: COMPARATOR
Intervention: Population-based sample (DEGS1)
Number of subjects: 1013
Study 26068325 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training group (TG)
Number of subjects: 120
Study 26068325 — intervention group
Group type: EXPERIMENTAL
Intervention: Maturational training group (MG)
Number of subjects: 120
Study 26068325 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study 24927164 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable hemostatic matrix (FLOSEAL, Baxter Healthcare Corporation)
Number of subjects: 600
Study 24927164 — intervention group
Group type: COMPARATOR
Intervention: Non-flowable topical hemostats (SURGICEL Nu-Knit, Ethicon-Johnson & Johnson; GELFOAM, Pfizer)
Number of subjects: 600
Study 22819864 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (4000 IU/day, subcutaneously for 48 weeks)
Number of subjects: 70
Study 22819864 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 70
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program consisting of a 15-minute presentation
Number of subjects: 204
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a syringe rather than vacutainer
Number of subjects: 204
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Venipuncture for blood sampling
Number of subjects: 204
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial sampling
Number of subjects: 204
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample volume
Number of subjects: 204
Study 19854334 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval from sampling to analysis
Number of subjects: 204
Study 17365948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM) protocol
Number of subjects: 0
Study 17365948 — intervention group
Group type: COMPARATOR
Intervention: Total-body mass (TBM) protocol
Number of subjects: 0
Study 15339769 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring
Number of subjects: 80
Study 15339769 — intervention group
Group type: COMPARATOR
Intervention: 20 microg ethinyl estradiol oral contraceptive pill
Number of subjects: 80
Study 11993702 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of therapeutic interventions
Number of subjects: 0
Study 11993702 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of diagnostic test accuracy
Number of subjects: 0
Study 9581698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (up to 1.2 g daily for 24 weeks)
Number of subjects: 30
Study 9581698 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (3 MU three times a week for 24 weeks)
Number of subjects: 30
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast preload sweetened with aspartame (300 kcal)
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast preload sweetened with sucrose (300 kcal)
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast preload sweetened with aspartame and supplemented with maltodextrin (700 kcal)
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy breakfast preloads
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy breakfast preloads
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 24
Study 7951479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean women
Number of subjects: 24
Study 3182481 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled codeine (50 mg)
Number of subjects: 13
Study 3182481 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine (10 mg)
Number of subjects: 13
Study 3182481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral codeine (60 mg)
Number of subjects: 13
Study 3182481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.15 mg/kg)
Number of subjects: 13
Study 30909248 — intervention group
Group type: EXPERIMENTAL
Intervention: 20Hz rTMS
Number of subjects: 52
Study 30909248 — intervention group
Group type: COMPARATOR
Intervention: 1Hz rTMS
Number of subjects: 52
Study 28052884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-12 toothpaste
Number of subjects: 76
Study 28052884 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 76
Study 25803666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) exercise program
Number of subjects: 196
Study 25803666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 196
Study 25803666 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 23631513 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser therapy
Number of subjects: 15
Study 21875440 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 57
Study 21875440 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 57
Study 19289711 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide respule therapy
Number of subjects: 9
Study 17942013 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2802
Study 17942013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2802
Study 17942013 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-of-processing training
Number of subjects: 2802
Study 17942013 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 2802
Study 15189292 — intervention group
Group type: EXPERIMENTAL
Intervention: GAS isolates differentiated by Vir typing
Number of subjects: 40
Study 15189292 — intervention group
Group type: EXPERIMENTAL
Intervention: GAS isolates differentiated by emm typing
Number of subjects: 40
Study 15189292 — intervention group
Group type: EXPERIMENTAL
Intervention: Most prevalent emm type
Number of subjects: 40
Study 15189292 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of emm type distribution
Number of subjects: 40
Study 15296684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural cardiac rehabilitation programme (12 weeks)
Number of subjects: 0
Study 15296684 — intervention group
Group type: COMPARATOR
Intervention: Waiting treatment group
Number of subjects: 0
Study 10537964 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg/day (n = 551)
Number of subjects: 817
Study 10537964 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 to 20 mg/day (n = 266)
Number of subjects: 817
Study 10537964 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg/day
Number of subjects: 817
Study 10537964 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 to 20 mg/day
Number of subjects: 817
Study 7744944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar prosthesis
Number of subjects: 0
Study 7744944 — intervention group
Group type: COMPARATOR
Intervention: Unipolar prosthesis
Number of subjects: 0
Study 7744944 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 0
Study 2248819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 0.5 micrograms kg‐1 min‐1
Number of subjects: 35
Study 2248819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6767826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 39
Study 6767826 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 39
Study 31857300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) therapy
Number of subjects: 1512
Study 31857300 — intervention group
Group type: COMPARATOR
Intervention: Standard-oxygen therapy
Number of subjects: 1512
Study 29157898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioinductive collagen implant
Number of subjects: 33
Study 25505013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 321
Study 25505013 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 321
Study 24588965 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-124
Number of subjects: 65
Study 24588965 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves analysis
Number of subjects: 65
Study 22918005 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement (Smartcem 2)
Number of subjects: 50
Study 22918005 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC) (GC Luting and Lining cement)
Number of subjects: 50
Study 20455988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control strategy
Number of subjects: 2876
Study 20455988 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 2876
Study 16967034 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlocking nails
Number of subjects: 53
Study 16967034 — intervention group
Group type: COMPARATOR
Intervention: Expandable nails
Number of subjects: 53
Study 16004252 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with differing RDA and REA values
Number of subjects: 0
Study 16004252 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpastes
Number of subjects: 0
Study 12349893 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration low-molecular-weight heparin therapy
Number of subjects: 0
Study 12349893 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative prophylaxis
Number of subjects: 0
Study 12349893 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis after hospital discharge
Number of subjects: 0
Study 10200438 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual 'go' signal with accompanying loud acoustic stimulus
Number of subjects: 14
Study 10200438 — intervention group
Group type: COMPARATOR
Intervention: Visual 'go' signal without accompanying loud acoustic stimulus
Number of subjects: 14
Study 7787356 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with rotating hemostatic valve and modified technique
Number of subjects: 20
Study 7787356 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine TBDC placement using Accustick system
Number of subjects: 20
Study 30117760 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative yoga (Group R)
Number of subjects: 42
Study 30117760 — intervention group
Group type: COMPARATOR
Intervention: Vigorous yoga (Group V)
Number of subjects: 42
Study 28338223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 79
Study 28338223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 79
Study 28338223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 26198921 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 at 2mg/kg
Number of subjects: 10
Study 26198921 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 at 6mg/kg
Number of subjects: 10
Study 26198921 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1
Number of subjects: 10
Study 24030613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 341
Study 24030613 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic supportive therapy
Number of subjects: 341
Study 19939653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 150
Study 19939653 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester spread (2 g/day)
Number of subjects: 150
Study 19939653 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 150
Study 19880936 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention consisting of behaviour change counselling, motivational enhancement therapy, and referral to a community alcohol treatment agency.
Number of subjects: 112
Study 19880936 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention delivered by a practice nurse (control group).
Number of subjects: 112
Study 16800138 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (5 cc of 1% mepivacaine solution)
Number of subjects: 131
Study 16800138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthesia)
Number of subjects: 131
Study 15184979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg once daily for 6 weeks)
Number of subjects: 20
Study 15184979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10910028 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg daily)
Number of subjects: 9
Study 10910028 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg daily)
Number of subjects: 9
Study 9341968 — intervention group
Group type: EXPERIMENTAL
Intervention: apoE3/2 phenotype in psoriasis vulgaris patients
Number of subjects: 100
Study 9341968 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 9341968 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon 2 allele frequency in psoriasis vulgaris patients
Number of subjects: 100
Study 8449075 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (1-2 L/min) for 10 min
Number of subjects: 14
Study 8449075 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study 3022512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 10
Study 30059188 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (300 mg) twice daily
Number of subjects: 90
Study 30059188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (8 mg) twice daily
Number of subjects: 90
Study 30059188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 90
Study 29078970 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus gabapentin (300 mg/d)
Number of subjects: 46
Study 29078970 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (300 mg/d) alone
Number of subjects: 46
Study 26179187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (0.75 mg)
Number of subjects: 492
Study 23294495 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 172
Study 23294495 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUTT)
Number of subjects: 172
Study 23294495 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the Orthostatic Grading Scale (KOGS)
Number of subjects: 172
Study 23294495 — intervention group
Group type: EXPERIMENTAL
Intervention: KOGS
Number of subjects: 172
Study 21717138 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 100 mg immediate-release capsules
Number of subjects: 0
Study 18435184 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment using a shade guide (Vitapan Classical)
Number of subjects: 92
Study 16583183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 232
Study 16583183 — intervention group
Group type: COMPARATOR
Intervention: Alexandrite laser
Number of subjects: 232
Study 16583183 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 232
Study 14630560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy (9, 12, 15 or 18 Gy at 1 mm tissue depth)
Number of subjects: 181
Study 14630560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation therapy without geographical miss (non-GM)
Number of subjects: 181
Study 14630560 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical miss (GM)
Number of subjects: 181
Study 10782630 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% added to timolol 0.5% and dorzolamide 2%
Number of subjects: 52
Study 10782630 — intervention group
Group type: COMPARATOR
Intervention: Control group (timolol 0.5% and dorzolamide 2% without latanoprost)
Number of subjects: 52
Study 8615494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with epinephrine 1:300,000
Number of subjects: 38
Study 8615494 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 38
Study 1451721 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clomipramine b.d. during active therapy
Number of subjects: 37
Study 1451721 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during the initial week
Number of subjects: 37
Study 1451721 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine treatment
Number of subjects: 37
Study 3938935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 0
Study 3938935 — intervention group
Group type: COMPARATOR
Intervention: Control group (children exposed frequently to malaria)
Number of subjects: 0
Study 29534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision followed by intralesional 5-fluorouracil/triamcinolone acetonide (5-FU/TAC)
Number of subjects: 60
Study 29534885 — intervention group
Group type: COMPARATOR
Intervention: Excision followed by radiotherapy
Number of subjects: 60
Study 26406193 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (RSWT)
Number of subjects: 24
Study 26406193 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (ManT)
Number of subjects: 24
Study 26412456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 582
Study 26412456 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² every 3 weeks)
Number of subjects: 582
Study 26412456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 582
Study 26412456 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 582
Study 23698248 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week isolated core training program (n = 18)
Number of subjects: 36
Study 23698248 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 36
Study 21402651 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training combined with transcranial direct current stimulation (n=10)
Number of subjects: 30
Study 21402651 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training combined with sham transcranial direct current stimulation (n=10)
Number of subjects: 30
Study 21402651 — intervention group
Group type: COMPARATOR
Intervention: Overground walking exercises (Control group, n=10)
Number of subjects: 30
Study 18317067 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with carboplatin (AUC 5), irinotecan (100 mg/m²), and paclitaxel (175 mg/m²) followed by concurrent chemotherapy with carboplatin (AUC 2) and paclitaxel (45 mg/m² weekly) and gefitinib (250 mg daily) with 3-dimensional TCRT to 74 Gy
Number of subjects: 23
Study 18317067 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 23
Study 18317067 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and gefitinib concurrent with 3-dimensional TCRT
Number of subjects: 23
Study 16956824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating deferoxamine and deferiprone
Number of subjects: 60
Study 16956824 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine monotherapy
Number of subjects: 60
Study 15329007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20
Study 15329007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11705343 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio intervention (group sessions with tasks from the Instrumental Enrichment Program, Philosophy for Children Program, and Project Intelligence)
Number of subjects: 109
Study 11705343 — intervention group
Group type: EXPERIMENTAL
Intervention: Portfolio intervention
Number of subjects: 109
Study 9202948 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFD (1 g.day‐1 for 4 days)
Number of subjects: 14
Study 9202948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 7949664 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto Stentless Porcine Valve (SPV)
Number of subjects: 21
Study 7949664 — intervention group
Group type: COMPARATOR
Intervention: Hancock II bioprosthesis
Number of subjects: 21